World's Best Scientists 2026 revealed!
Pietro Lampertico

Pietro Lampertico

D-Index & Metrics

Medicine

D-Index
80
Citations
32678
World Ranking
16923
National Ranking
677

Overview

Pietro Lampertico is a researcher affiliated with the University of Milan in Italy. Their work predominantly centers on the field of Medicine, with a strong focus on Epidemiology and Hepatology. They have contributed extensively to research on infectious diseases, surgery, and oncology, with a particular emphasis on liver-related conditions.

The scientist's research topics mainly cover areas related to hepatology and liver diseases, including:

  • Hepatitis C virus research
  • Liver Disease Diagnosis and Treatment
  • Hepatitis B Virus Studies
  • Liver Disease and Transplantation
  • Hepatitis Viruses Studies and Epidemiology
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Liver Diseases and Immunity

Pietro Lampertico has published frequently in several specialized venues, with a substantial number of publications in:

  • Journal of Hepatology
  • Digestive and Liver Disease
  • Liver International
  • Zeitschrift für Gastroenterologie
  • Alimentary Pharmacology & Therapeutics

Among their recent publications are articles on hepatocellular carcinoma, liver cirrhosis, and hepatitis D virus research. Notable papers include:

  • "Epidemiology and surveillance for hepatocellular carcinoma: New trends," 2020, Journal of Hepatology
  • "High rates of 30-day mortality in patients with cirrhosis and COVID-19," 2020, Journal of Hepatology
  • "aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis," 2020, Journal of Hepatology
  • "Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease," 2021, Gut
  • "A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D," 2023, New England Journal of Medicine

Collaborations are a significant aspect of their research output. Frequent co-authors include:

  • Elisabetta Degasperi
  • Maurizia Rossana Brunetto
  • Roberta D'Ambrosio
  • Heiner Wedemeyer
  • Riccardo Perbellini

Best Publications

  • EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

    Pietro Lampertico;Kosh Agarwal;Thomas Berg;Maria Buti

  • EASL Clinical Practice Guidelines: Management of chronic hepatitis B

    C.P.G.P.P. Marcellin;G. Dusheiko;F. Zoulim;R. Esteban

  • Epidemiology and surveillance for hepatocellular carcinoma: New trends

    Amit G. Singal;Pietro Lampertico;Pierre Nahon

  • Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy

    George V. Papatheodoridis;Henry Lik Yuen Chan;Bettina E. Hansen;Harry L A Janssen;Harry L A Janssen

  • Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.

    George V. Papatheodoridis;Pietro Lampertico;Spilios Manolakopoulos;Anna Lok

  • PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy

    George Papatheodoridis;George Dalekos;Vana Sypsa;Cihan Yurdaydin

  • Update of the statements on biology and clinical impact of occult hepatitis B virus infection

    Giovanni Raimondo;Stephen Locarnini;Teresa Pollicino;Massimo Levrero

  • Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage

    Claire Dunn;R. Maurizia Brunetto;Gary Reynolds;Theodoros Christophides

  • A global scientific strategy to cure hepatitis B

    Peter A Revill;Francis V Chisari;Joan M Block;Maura Dandri

  • Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

    Pietro Lampertico;Mauro Viganò;Elena Manenti;Massimo Iavarone

  • Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.

    Carolina Boni;Diletta Laccabue;Pietro Lampertico;Tiziana Giuberti

  • IL-10–Producing Regulatory B Cells in the Pathogenesis of Chronic Hepatitis B Virus Infection

    Abhishek Das;Gidon Ellis;Celeste Pallant;A. Ross Lopes

  • High rates of 30-day mortality in patients with cirrhosis and COVID-19.

    Massimo Iavarone;Roberta D'Ambrosio;Alessandro Soria;Michela Triolo

  • Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

    Pietro Lampertico;Mauro Viganò;Elena Manenti;Massimo Iavarone

  • Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B

    Paola Fisicaro;Valeria Barili;Barbara Montanini;Greta Acerbi

  • Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.

    Eugene Schiff;Cjing Lung Lai;Stephanos Hadziyannis;Peter Nuehaus

  • Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine

    Vito Di Marco;Alfredo Marzano;Pietro Lampertico;Pietro Andreone

  • The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.

    George V. Papatheodoridis;Ramazan Idilman;George N. Dalekos;Maria Buti

  • Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients

    W. Ray Kim;Thomas Berg;Tarik Asselah;Robert Flisiak

  • Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

    Pietro Lampertico;Ersilio Del Ninno;Mauro Viganò;Raffaella Romeo

Frequent Co-Authors

María I. Colombo
María I. Colombo National University of Cuyo
Massimo Colombo
Massimo Colombo Humanitas University
Fabio Facchetti
Fabio Facchetti University of Brescia
George V. Papatheodoridis
George V. Papatheodoridis National and Kapodistrian University of Athens
Maria Buti
Maria Buti Instituto de Salud Carlos III
Harry L.A. Janssen
Harry L.A. Janssen Erasmus University Rotterdam
Massimo Puoti
Massimo Puoti University of Milano-Bicocca
Antonio Craxì
Antonio Craxì University of Palermo

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online nursing degrees can be a flexible alternative for those interested in healthcare careers without necessarily attending medical school. For registered nurses looking to advance, rn to bsn no clinical hours programs remove the traditional clinical requirements, making it easier for working professionals to balance studies and responsibilities.

Nurse practitioners or nurses seeking higher credentials can consider advanced options like dnp programs online. These Doctor of Nursing Practice programs are increasingly available in accessible, virtual formats designed for experienced nurses. If speed is your priority, explore the shortest dnp program options which offer accelerated tracks for fast career progression.

For those at the beginning of their nursing journey, lpn online programs provide streamlined pathways to enter practical nursing, often in less time and with greater flexibility compared to traditional routes.

Whether you're just starting out or aiming to take your nursing career to new heights, online pathways offer a range of flexible opportunities that could match your schedule, career goals, and interests.

Best Scientists Citing Pietro Lampertico

Trending Scientists

Recently Published Articles